- Enanta Pharmaceuticals has initiated a Phase II clinical trial for the treatment of community-acquired pneumonia in the United States and Canada for EDP-420, an investigational bridged bicyclic macrolide antibiotic for the treatment of community-acquired respiratory tract infections.
- Nuvelo has been granted fast-track designation by the FDA for its lead product candidate, alfimeprase, for the treatment of acute peripheral arterial occlusion.
- Genta has announced that the first patient has been entered into a new clinical study that will evaluate the bioactivity and safety of the company’s lead anticancer drug, oblimersen sodium (Genasense) injection, administered by intermittent subcutaneous injection.
- EntreMed has initiated Phase II studies with MKC-1, a novel, orally active, small molecule cell cycle inhibitor with a unique mechanism of action. Patients with advanced or metastatic breast cancer who have failed conventional therapies are expected to be enrolled.
- BioMarin Pharmaceutical has announced that the FDA has granted fast-track designation for sapropterin dihydrochloride (Phenoptin) for phenylketonuria.
- Affymax has initiated a Phase II clinical trial of Hematide, a synthetic peptide-based erythropoiesis-stimulating agent, to treat anemia in cancer patients.
- Schering-Plough reported that the FDA has granted fast designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment of chronic hepatitis C virus infection.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content